Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
60.67
+0.85 (1.42%)
At close: Mar 9, 2026, 4:00 PM EDT
60.50
-0.17 (-0.28%)
After-hours: Mar 9, 2026, 7:51 PM EDT
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $264.03M in the quarter ending December 31, 2025, with 10,461.32% growth. This brings the company's revenue in the last twelve months to $1.09B, up 43,539.24% year-over-year. In the fiscal year ending September 30, 2025, Arrowhead Pharmaceuticals had annual revenue of $829.45M with 23,258.15% growth.
Revenue (ttm)
$1.09B
Revenue Growth
+43,539.24%
P/S Ratio
7.79
Revenue / Employee
$1,534,432
Employees
711
Market Cap
8.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 829.45M | 825.90M | 23,258.15% |
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | Pro | Pro | Pro |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Madrigal Pharmaceuticals | 958.40M |
| Axsome Therapeutics | 638.50M |
| Krystal Biotech | 389.13M |
| ImmunityBio | 113.29M |
| Cytokinetics | 88.04M |
| Praxis Precision Medicines | 7.46M |
ARWR News
- 13 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results - Business Wire
- 4 weeks ago - Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 - PRNewsWire
- 5 weeks ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Business Wire
- 6 weeks ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants - Business Wire